GlaxoSmithKline takes a $400 million hit

The health blog of The Wall Street Journal was the first to report Jan. 29 that GlaxoSmithKline is taking a $400 million hit related to federal and state probes into the drug giant’s research and marketing shenanigans. Glaxo announced the charge in its fourth...

Inauspicious omen for journalism’s fate

I came back from vacation this week only to be greeted with bad news: Pharmalot, Ed Silverman’s blog on the pharmaceutical industry, is no more. How disappointing! The demise of Pharmalot not only creates a big hole in coverage — for me and many other...